Cargando…
Sintilimab: A Promising Anti-Tumor PD-1 Antibody
Sintilimab (Tyvyt(®)) is a monoclonal antibody against programmed cell death protein 1 (PD-1). It could block the interaction between PD-1 and its ligands and help the anti-tumor effect of T-cells to recover. Sintilimab is developed by Innovent Biologics and Eli Lilly and Company and has been approv...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726413/ https://www.ncbi.nlm.nih.gov/pubmed/33324564 http://dx.doi.org/10.3389/fonc.2020.594558 |